Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of XL147 in Advanced or Recurrent Endometrial Carcinoma
2009-016707-30Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pilaralisib in endometrial cancer (EC), sponsored by Sanofi. Primary endpoints: Objective response rate (ORR) and 6-month progression-free survival rate (PFS6). Started Feb 2010; status: terminated.
02
Drugs
pilaralisib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2009-016707-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016707-30.